SCHEMBL5428437

SCHEMBL5428437

COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OC[C@@H]1CCCNC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 16/20 0.80
KDR P35968 16/20 0.80
FGFR1 P11362 14/20 0.80
FLT4 P35916 12/20 0.80
EGFR P00533 12/20 0.80
EPHA2 P29317 4/20 0.73
EPHB2 P29323 2/20 0.67
EPHB4 P54760 2/20 0.63
BMPR1B O00238 1/20 0.59
PLK4 O00444 1/20 0.59
CIT O14578 1/20 0.59
GAK O14976 1/20 0.59
EPHB6 O15197 1/20 0.59
RIPK2 O43353 1/20 0.59
ROCK2 O75116 1/20 0.59
STK10 O94804 1/20 0.59
MAP4K4 O95819 1/20 0.59
ABL1 P00519 1/20 0.59
ERBB2 P04626 1/20 0.59
LCK P06239 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5783910 1.00 FLT1 (0.80) FLT1KDRFGFR1FLT4EGFR
SCHEMBL2140901 0.90 FLT1 (0.98) FLT1KDRFGFR1FLT4EGFR
Hydrochloric Acid SCHEMBL27218181 0.89 FLT1 (1.00) FLT1KDRFGFR1FLT4EGFR
SCHEMBL1469920 0.86 KDR (1.00) FLT1KDRFGFR1FLT4EGFR
SCHEMBL1467578 0.86 KDR (1.00) FLT1KDRFGFR1FLT4EGFR
SCHEMBL1467082 0.86 KDR (1.00) FLT1KDRFGFR1FLT4EGFR
SCHEMBL2137353 0.84 EGFR (0.98) FLT1KDRFGFR1FLT4EGFR
SCHEMBL8454429 0.84 FLT1 (0.65) FLT1KDRFGFR1FLT4EGFR
Hydrochloric Acid SCHEMBL2140851 0.83 EGFR (1.00) FLT1KDRFGFR1FLT4EGFR
SCHEMBL5433644 0.83 FLT1 (0.83) FLT1KDRFGFR1FLT4EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070027145-A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases ASTRAZENCA (SE) 2007-02-01 US disclosed
EP-1653965-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES Astrazeneca AB (SE) 2006-05-10 EP disclosed
WO-2005013998-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES ASTRAZENECA AB (SE) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027145-A1 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases FLT4, FLT1, VEGFA FLT1 2/4885KDR 4/4885FGFR1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.